Scholarlink

<p>Surgical excision is the first-line treatment for non-melanoma skin cancer (NMSC); however, alternative approaches are necessary in cases where surgery is not feasible. High-dose brachytherapy with an unsealed rhenium-188 (188Re) resin is a&#xa0;noninvasive treatment option for NMSCs up to 2–3 mm tumor thickness. This case report describes the experience with 188Re brachytherapy for treating a&#xa0;challenging nodular basal cell carcinoma (BCC). The prescribed absorbed dose was 35 Gy at the deepest infiltration point, corresponding to a&#xa0;total applied dose of 68 Gy. At 6&#xa0;months post-treatment, histological analysis confirmed complete tumor resolution with no residual neoplastic cells. In over 48&#xa0;months of follow-up, no recurrence was observed. Cosmetic outcomes were excellent, with high patient satisfaction.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Rhenium-188 Brachytherapy of a Nodular Basal Cell Carcinoma: a Case Report from the Central Hospital Bolzano/Bozen, South Tyrol

  • 期刊论文

  • 发表日期：

    2025年3月17日

查看全文
  • Ilaria Perrone,
  • Alan Azzolini,
  • Leda Lorenzon,
  • Mohsen Farsad,
  • Klaus Eisendle

摘要

Surgical excision is the first-line treatment for non-melanoma skin cancer (NMSC); however, alternative approaches are necessary in cases where surgery is not feasible. High-dose brachytherapy with an unsealed rhenium-188 (188Re) resin is a noninvasive treatment option for NMSCs up to 2–3 mm tumor thickness. This case report describes the experience with 188Re brachytherapy for treating a challenging nodular basal cell carcinoma (BCC). The prescribed absorbed dose was 35 Gy at the deepest infiltration point, corresponding to a total applied dose of 68 Gy. At 6 months post-treatment, histological analysis confirmed complete tumor resolution with no residual neoplastic cells. In over 48 months of follow-up, no recurrence was observed. Cosmetic outcomes were excellent, with high patient satisfaction.